FEMY Company Profile and Key Details

Q: Who are the executives of FEMY?

Dr. Edward G. Evantash M.D.Chief Medical OfficerMs. Christine ThomasSenior Vice President of Regulatory & Clinical AffairsMs. Mary An Merchant J.D., Ph.D.Vice President of Counsel & Intellectual PropertyMr. Steven P. DamonVice President of Bus. Devel.Mr. Todd A. Creech MBAChief Financial AdvisorMr. Dov ElefantChief Financial OfficerMr. Daniel Scott CurrieSenior Vice President of Operations & Sec.Ms. Kathy Lee-SepsickFounder & Chief Executive Officer and PresDr. Jeffrey Marcus M.D., M.S.Chief Medical Advisor

NASDAQ : FEMY

Femasys

$3.47

-0.52-13.03%

At Close 4:00 PM

$4.18

+0.22+5.56%

After-Market 08:30 PM

50.48

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Femasys Inc. (FEMY) stock declined over -13.03%, trading at $3.47 on NASDAQ, down from the previous close of $3.99. The stock opened at $3.62, fluctuating between $3.41 and $3.62 in the recent session.

Stock Snapshot

3.99

Prev. Close

10.48M

Market Cap

3.41

Day Low

-9.59

P/E Ratio

-0.362

EPS (TTM)

-0.53

Cash Flow per Share

3.62

Open

3.02M

Number of Shares

3.62

Day High

77.46%

Free Float in %

0.85

Book Value

35.61K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	3.97	4.01	3.39	3.47	35.81K
Jul 10, 2026	3.89	4.07	3.88	3.99	27.06K
Jul 09, 2026	3.93	4.06	3.80	3.85	10.05K
Jul 08, 2026	3.80	4.02	3.68	3.96	16.56K
Jul 07, 2026	4.20	4.20	3.84	3.87	21.22K
Jul 06, 2026	4.18	4.50	4.08	4.08	42.64K
Jul 02, 2026	4.42	4.78	4.17	4.17	65.37K
Jul 01, 2026	4.14	4.55	4.14	4.35	51.53K
Jun 30, 2026	3.74	4.28	3.64	4.18	39.46K
Jun 29, 2026	3.80	3.93	3.73	3.74	24.93K
Jun 26, 2026	3.63	3.93	3.56	3.80	51.55K
Jun 25, 2026	3.66	3.70	3.50	3.60	48.84K
Jun 24, 2026	3.96	4.02	3.66	3.67	49.02K
Jun 23, 2026	4.07	4.16	4.01	4.01	14.52K
Jun 22, 2026	4.02	4.45	3.86	4.08	43.93K
Jun 18, 2026	4.29	4.33	3.85	4.04	43.8K
Jun 17, 2026	3.86	4.49	3.86	4.19	59.61K
Jun 16, 2026	4.01	4.15	3.77	3.84	53.51K
Jun 15, 2026	4.35	4.35	3.87	3.98	97.3K
Jun 12, 2026	4.76	4.85	4.02	4.18	89.91K

Contact Details

Suwanee, GA 30024

United States

https://www.femasys.com 770 500 3910

About Company

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

Stock Peers

ATRI

0.26+0.06%

Atrion Corporation$459.92 ICUI

3.18+2.06%

ICU Medical, Inc.$157.60 RGEN

0.64001+0.44%

Repligen Corporation$144.88 LMAT

-2.45-2.38%

LeMaitre Vascular, Inc.$100.29 HOLX

0.0000020.00%

Hologic, Inc.$76.01 MMSI

-0.18-0.25%

Merit Medical Systems, Inc.$73.26 COO

0.62+0.88%

The Cooper Companies, Inc.$71.32 UTMD

2.05+3.02%

Utah Medical Products, Inc.$70.01 PDEX

-1.34-2.13%

Pro-Dex, Inc.$61.55 MDLN

-0.46-1.12%

Medline Inc.$40.58

Company Overview

Femasys Inc. (NASDAQ:FEMY) closed at $3.47 USD, losing -$0.52 (-13.03%) from the previous close of $3.99. The stock is currently within 5% of its 52-week low $3.41 and $22.20. With a market capitalization of about $10.48 million, Femasys Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-2.13). Key stats such as the average daily volume over the past year has been around 62.51 thousand shares, volume is running light vs its 52-week average. Headquartered in Suwanee, GA, Femasys Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Kathy Lee-Sepsick, the company employs approximately 54 people and listed since June 18, 2021. Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States.

Technical Performance

FEMY has shown mixed momentum, gaining 14.11% over the past week and -3.47% over the past quarter, though year-to-date performance is up 17.79%. Short-term trend indicators are bullishly aligned (SMA20 6.04%, SMA50 -8.85%, SMA200 -22.46%). The stock’s 14-day RSI is 49.56 (neutral), while the ATR of 0.04 points to moderate volatility. The stock remains hovering near 52-week lows, trading -68.28% below its high and over 82.03% above its low. Average 10-day trading volume of 25.56 thousand shares is below the 3-month average of 56.25 thousand, indicating normal recent market interest.

Valuation Metrics

Femasys Inc. trades at a P/E ratio of -0.54, slightly below the S&P 500 average, with a price-to-sales ratio of 4.37 and a price-to-book ratio of 1.57 suggesting the stock is closer to book value. The P/FCF stands at -0.56, also above market averages.

Dividend & Fair Value

Femasys Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.24. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Femasys Inc. generated EPS of -$0.72 over the past year. Five-year average earnings growth is 2.49%. Wall Street analysts project EPS growth of 31.35% annually over the next five years. The latest quarter delivered EPS of $0.00. The next quarter is forecast at -$0.09. Next year's EPS is expected at $45.05. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $1.50. The high target offers 130.55% upside. The low target suggests -56.77% downside. The mean target is $5.33. This offers 53.6% upside. Femasys Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 08, 2026, missed forecasts by -107.35%. The prior quarter beat by -88.0%. Over the last six quarters, Apple has recorded several small beats. These include 35.29% in May 08, 2025.

Shareholding & Insider Activity

Femasys Inc. has 32.58 million shares outstanding. The public float is 27.74 million shares, elevated short interest at 1.52% of float. This equals 363.17 thousand shares. The short ratio is 2.3 days. Institutional investors hold 15.88% of the float. Insiders own 11.3%. Uzialko Edward R holds 127.79 thousand shares, Dyett John has 114.71 thousand shares and Adams John Q JR has 40.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Femasys generated $1.07M in revenue, or $0.07 per share. Gross margin was -20.16%, operating margin -1353.44%, and net profit margin -1329.06%. Returns are negative, with ROA at -51.33% and ROE at -77.63%.
On valuation metrics, Femasys trades at a P/E of -0.54, P/S of 4.37 and P/B of 1.57. The current ratio is 3.91 and quick ratio is 1.98. Operationally, the company’s inventory turnover is 0.18 and cash conversion cycle is 1503.13 days. Debt-to-equity is 0.65, supported by a cash flow-to-debt ratio of -3.82.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Femasys posted revenue of $1.07M, down slightly from $1.21M in the prior quarter. Gross profit was - $216.08K (margin -20.16%). Operating income was - $14.51M (margin -1353.4%). Net income was- $14.25M (EPS - $0.93).
The company ended the quarter with $21.72M in cash and short-term investments, a total debt of $6.70M, and net debt of - $15.02M. Total assets were $27.76M, with equity of $18.35M. Financials further reflected weakness, with operating cash flow of - $11.28M, free cash flow of - $11.42M, and capital expenditures of - $143.92K.

Price Forecast & Outlook

Our AI price prediction model suggests that Femasys Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -36.89%, with price expected at $2.19 by July 27, 2026, within a range of $1.11 to $3.16 3-Month Outlook: Projected fall of -49.86%, reaching $1.74 by October 08, 2026, with a range of $1.13 to $2.42. 1-Year Outlook: Projected loss of -72.05%, with price at $0.97 by July 13, 2027, within a range of $0.00 to $1.94.

Key Takeaways

Femasys Inc. (NASDAQ:FEMY) shares are up 17.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Femasys Inc. trading at a premium to the broader market with a P/E of -0.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.22, suggesting 194.52% upside. Our AI forecast model points to short-term weakness (-36.89% over two weeks), a medium-term fall (-49.86% over three months), and a longer-term loss (-72.05% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Femasys Inc. (FEMY) stock price?

Femasys Inc. (NASDAQ: FEMY) stock price is $3.47 in the last trading session. During the trading session, FEMY stock reached the peak price of $3.62 while $3.41 was the lowest point it dropped to. The percentage change in FEMY stock occurred in the recent session was -13.03% while the dollar amount for the price change in FEMY stock was - $0.52.

FEMY's industry and sector of operation?

The NASDAQ listed FEMY is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Femasys Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FEMY?

Dr. Edward G. Evantash M.D.
Chief Medical Officer
Ms. Christine Thomas
Senior Vice President of Regulatory & Clinical Affairs
Ms. Mary An Merchant J.D., Ph.D.
Vice President of Counsel & Intellectual Property
Mr. Steven P. Damon
Vice President of Bus. Devel.
Mr. Todd A. Creech MBA
Chief Financial Advisor
Mr. Dov Elefant
Chief Financial Officer
Mr. Daniel Scott Currie
Senior Vice President of Operations & Sec.
Ms. Kathy Lee-Sepsick
Founder & Chief Executive Officer and Pres
Dr. Jeffrey Marcus M.D., M.S.
Chief Medical Advisor

How FEMY did perform over past 52-week?

FEMY's closing price is 1.76% higher than its 52-week low of $3.41 where as its distance from 52-week high of $22.20 is -84.37%.

How many employees does FEMY have?

Number of FEMY employees currently stands at 54.

Link for FEMY official website?

Official Website of FEMY is: https://www.femasys.com

How do I contact FEMY?

FEMY could be contacted at phone 770 500 3910 and can also be accessed through its website. FEMY operates from 3950 Johns Creek Court, Suwanee, GA 30024, United States.

How many shares of FEMY are traded daily?

FEMY stock volume for the day was 35.61K shares. The average number of FEMY shares traded daily for last 3 months was 62.51K.

What is the market cap of FEMY currently?

The market value of FEMY currently stands at $10.48M with its latest stock price at $3.47 and 3.02M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	54
Beta	-2.13
Sales or Revenue	$1.07M
5Y Sales Change%	-0.118%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Instruments & Supplies

FEMY Company Profile and Key Details

Femasys

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook

Dividend & Fair Value